Ranbaxy
Pharmaceuticals
Inc. (RPI),
a wholly
owned subsidiary
of Ranbaxy
Laboratories
Limited.
(RLL), was
established
in the U.S.
in 1994.
RPI began
marketing
FDA approved
generic
products
in the U.S.
in 1998
after receiving
its first
FDA approval
for Cefaclor,
a broad
spectrum
anti-infective
agent. Read
More >>
Ranbaxy has a structured Program for individuals who wish to disclose any issues or ask any questions related to Ranbaxy's policies, procedures, conduct or practices. For more details please visit the following links:
